Virax Biolabs Group Limited - VRAX EV/Sales Multiple

Public company logo of viraxbiolabs.com (VRAX)

The viral diagnostics market is extremely volatile due to its dependence on pandemics and pressure from major players. The EV/Sales multiple history confirms the asset's current dynamics, where -576000.00 determines this parameter level. The Virax Biolabs Group (VRAX) business relies on steady demand across all economic phases with an autumn peak, while laboratories are undergoing technical upgrades to launch new test lines.

VRAX: Virax Biolabs Corp Company Value to Revenue 11/23/2025 - 11/20/2026

Virax Biolabs Corp - analytical breakdowns and key metrics (VRAX)

- money and cash flow information:
Initial company analysis:VRAX, viraxbiolabs.com
Flagship merchandise of Virax Biolabs Group Ltd

Virax Biolabs Group (VRAX) molecular marker patents ensure margin stability within an oversaturated diagnostics sector, which directly impacts the market value of its assets. By analyzing the business valuation via EV/Sales, an investor observes the ratio of enterprise value (market capitalization plus net debt) to revenue, allowing for the determination of the premium paid for sales and an assessment of the asset's investment attractiveness relative to its debt load.

Competitor analysis

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Enterprise Value-to-Revenue Ratio ainos.com|CODX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio HeartSciences (HSCS)|Company Value to Revenue Biomerica Inc. BMRA|EV/Sales Multiple CDIO (Cardio Diagnostics)|ONCO - Company Value to Revenue|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue